- If you are wondering whether Hologic’s current share price still offers value, the key question is how its fundamentals stack up against what the market is willing to pay.
- The stock last closed at US$75.74, with returns of 0.5% over 7 days, 1.5% over 30 days, 1.6% year to date, 17.4% over 1 year, a 2.5% decline over 3 years, and 7.0% over 5 years. Taken together, this gives a mixed picture of recent performance and changing sentiment.
- Recent news around Hologic has mainly focused on its position in women’s health technologies and how investors are assessing its longer term role in that space. This context helps explain why the share price has been relatively resilient while medium term returns have been more muted.
- On our checks, Hologic currently records a valuation score of 3 out of 6. Next, we will compare what different valuation methods suggest about the stock’s pricing today and then finish with a broader framework that can help you interpret those signals more effectively.
Approach 1: Hologic Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a business might be worth by projecting future cash flows and discounting them back to today’s dollars. It is essentially asking what Hologic’s future cash generation could be worth right now.
Hologic’s latest twelve month free cash flow is about $942.7 million. Using a 2 Stage Free Cash Flow to Equity model, analysts and extrapolated estimates project free cash flow reaching about $1.52 billion by 2035, with intermediate years such as 2026 at $1.01 billion and 2028 at $1.14 billion. All of these cash flows are in dollars and are discounted back to reflect their value today.
On this basis, the model arrives at an estimated intrinsic value of US$107.83 per share. Compared with the recent share price of US$75.74, this implies the stock is about 29.8% undervalued according to this DCF approach.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Hologic is undervalued by 29.8%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.
Approach 2: Hologic Price vs Earnings
For profitable companies, the P/E ratio is a useful yardstick because it compares what you pay per share with the earnings that each share is generating. It gives you a quick sense of how many dollars investors are currently willing to pay for each dollar of profit.
What counts as a “normal” P/E often comes down to two things: growth expectations and risk. Higher expected earnings growth or lower perceived risk can support a higher multiple, while slower growth or higher risk usually call for a lower one.
Hologic currently trades on a P/E of 31.09x. That sits slightly above the Medical Equipment industry average of about 28.03x, and below the peer group average of 50.08x. Simply Wall St’s Fair Ratio for Hologic is 30.73x, which is its proprietary view of what a reasonable P/E could be after factoring in the company’s earnings growth profile, margins, industry, market cap and risk characteristics. This tailored Fair Ratio can be more informative than a simple comparison with peers or the sector because those broader groups may differ meaningfully on these drivers.
With Hologic’s actual P/E of 31.09x sitting very close to the Fair Ratio of 30.73x, the shares look priced at about the level this framework would suggest.
Result: ABOUT RIGHT
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Hologic Narrative
Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simple stories that you and other investors build around Hologic by linking your view of its business, forecasts for future revenue, earnings and margins, and the fair value you think those numbers support.
On Simply Wall St, Narratives sit inside the Community page and work like an accessible toolkit, helping you connect Hologic’s story to a set of financial assumptions, calculate a fair value, and then compare that to the current price to understand how your story aligns with a decision to buy, hold, or sell.
Narratives refresh automatically when new information arrives, such as the pending US$79 per share cash acquisition proposal and updated analyst targets between US$65 and US$94. One investor might build a more cautious Hologic Narrative closer to US$65, while another might lean on the US$94 view, and you can see how each story translates into a different fair value compared to today’s share price.
Do you think there's more to the story for Hologic? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com